Summary
We have studied the pharmacokinetics of orally administered chlorambucil and melphalan in patients with hematologic malignancies and solid tumors. With a standard oral dose of 0.6 mg/kg, chlorambucil showed much more rapid systemic appearance than did melphalan and had a mean peak plasma concentration and area under the plasma disappearance curve which was 3–4 times greater than that observed in patients receiving melphalan. Melphalan had extremely variable systemic availability which was not observed with chlorambucil, and was not related to problems in tablet formulation. Chlorambucil undergoes extensive active metabolism to phenylacetic acid mustard, whereas melphalan undergoes rapid chemical degradation and has little, if any, active metabolism. On a pharmacokinetic basis, chlorambucil’s greater in vitro stability, its more rapid and predictable systemic availability after oral dosing, and its extremely low urinary excretion make it a more predictible alkylating agent for clinical use than melphalan, especially for patients with reduced renal function.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alberts DS, Chang SY, Chen H-SG, Evans TL, Moon TE (1980) Oral melphalan kinetics. Clin Pharmacol and Ther 26:737–745
Alberts DS, Chang SY, Chen H-SG, Gross JF, Walson PD, Moon TE, Salmon SE (1978) Variability of melphalan absorption in man. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 19:C–112
Alberts DS, Chang SY, Chen H-SG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF (1979) Pharmacokinetics of melphalan in man: Intravenous administration. Clin Pharmacol and Ther 26:73–80
Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67:679–681
Chang SY, Evans TL, Alberts DS (1979) The stability of melphalan in the presence of chloride ion. J Pharm Pharmacol 3:853–854
Chang SY, Evans TL, Alberts DS, Sipes IG (1978) The stability of L-phenylalanine mustard in bile. Life Sci 23:1697–1702
Chang SY, Larcom BJ, Alberts DS, Larsen B, Walson PD, Sipes IG (1980) Mass spectrometry of chlorambucil, its degradation products and its metabolite in biological samples. J Pharm Sci 69:80–84
Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher E (1975) L-Phenylalanine mustard (l-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 292:117–122
Livingston RB, Carter SK (1970) Single agents in cancer chemotherapy. Plenum, New York, pp 81–111
Metzler CM (1969) NONLIN: A computer program for parameter estimation in nonlinear situations. Upjohn Company, Kalamazoo, Michigan, Technical Rep 7292/69/2792/005
Moore GE, Bross IDJ, Ausman R, Nadler S, Jones R, Jr, Slack N, Rimm AA (1968) Effects of chlorambucil (NSC 3088) in 374 patients with advanced cancer. Cancer Chemother Rep 52:661–666
Newell DR, Hart LI, Harrap, KR (1979) The estimation of chlorambucil, phenyl acetic mustard and prednimustine in human plasma by high-performance liquid chromatography. Journal of Chromatography 164:114–119
Sedman AJ, Wagner JG (1976) CSTRIP. A Fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65:1006–1010
Tattersall MHN, Jarman M, Newlands ES, Holyhead L, Milstead RAV, Weinberg A (1978) Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant diseases. Eur J Cancer 14:507–513
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Alberts, D.S., Chang, S.Y., Chen, HS.G., Larcom, B.J., Evans, T.L. (1980). Comparative Pharmacokinetics of Chlorambucil and Melphalan in Man. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive